HopeStage
Back to all studies
CompletedNCT00190931

Atomoxetine compared with placebo for work productivity in adults with ADHD

About this titleRead the official source — NCT00190931
Medication studyAges 18–49United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 49 years.

Listed locations
ColumbiaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2003
Recruitment status
Completed
Enrollment listed in the registry
400
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 49 Years
Official registry ID
NCT00190931
Official title
Show the full official title

A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Columbia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine Hydrochloride and placebo.

Who was this study for?

Listed age limits: 18 years to 49 years.

Want to explore more studies?

Explore studies